View DividendKBG 경영진경영진 기준 점검 0/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보Samuel Boo최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간3.2yrsCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간데이터 없음최근 경영진 업데이트공시 • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea공시 • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea공시 • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.모든 업데이트 보기Recent updates공시 • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).분석 기사 • Nov 20KBG's (KOSDAQ:318000) Soft Earnings Don't Show The Whole PictureInvestors were disappointed with the weak earnings posted by KBG Corp. ( KOSDAQ:318000 ). However, our analysis...Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩45.00 (vs ₩60.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩45.00 (down from ₩60.00 in 3Q 2024). Revenue: ₩4.71b (down 24% from 3Q 2024). Net income: ₩391.8m (down 25% from 3Q 2024). Profit margin: 8.3% (down from 8.4% in 3Q 2024). The decrease in margin was driven by lower revenue.공시 • Nov 07KBG Corp. announces Annual dividend, payable on April 10, 2026KBG Corp. announced Annual dividend of KRW 75.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩57.00 (vs ₩95.49 in 1Q 2024)First quarter 2025 results: EPS: ₩57.00 (down from ₩95.49 in 1Q 2024). Revenue: ₩6.09b (up 27% from 1Q 2024). Net income: ₩493.4m (down 41% from 1Q 2024). Profit margin: 8.1% (down from 17% in 1Q 2024). The decrease in margin was driven by higher expenses.공시 • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South KoreaNew Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₩42.0b market cap, or US$29.2m).Buy Or Sell Opportunity • Jan 06Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to ₩4,835. The fair value is estimated to be ₩4,029, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (2.2%).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.5b market cap, or US$28.9m).Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,890, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.분석 기사 • Dec 06Earnings Working Against KBG Corp.'s (KOSDAQ:318000) Share Price Following 26% DiveTo the annoyance of some shareholders, KBG Corp. ( KOSDAQ:318000 ) shares are down a considerable 26% in the last...Buy Or Sell Opportunity • Nov 18Now 23% overvaluedOver the last 90 days, the stock has fallen 25% to ₩4,930. The fair value is estimated to be ₩4,000, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,040, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years.New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩67.7b market cap, or US$50.7m).Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩7,750, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 4.7% over the past three years.분석 기사 • Aug 06The Market Doesn't Like What It Sees From KBG Corp.'s (KOSDAQ:318000) Earnings Yet As Shares Tumble 29%KBG Corp. ( KOSDAQ:318000 ) shareholders that were waiting for something to happen have been dealt a blow with a 29...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years.분석 기사 • May 21We Think That There Are Some Issues For KBG (KOSDAQ:318000) Beyond Its Promising EarningsKBG Corp.'s ( KOSDAQ:318000 ) healthy profit numbers didn't contain any surprises for investors. However the statutory...Upcoming Dividend • Dec 20Inaugural dividend of ₩99.50 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 1.8%.New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩83.9b market cap, or US$62.0m).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩11,370, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years.Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩115.7b market cap, or US$89.6m).Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩14,340, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years.Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩16,260, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 57%After last week's 57% share price gain to ₩16,830, the stock trades at a trailing P/E ratio of 42.8x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 220% over the past three years.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩9,650, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 76% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 2.4%.Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: ₩169 (vs ₩117 in 3Q 2021)Third quarter 2022 results: EPS: ₩169 (up from ₩117 in 3Q 2021). Revenue: ₩6.29b (down 9.1% from 3Q 2021). Net income: ₩1.39b (up 45% from 3Q 2021). Profit margin: 22% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,130, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩4,855, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩6,280, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total loss to shareholders of 27% over the past year.Upcoming Dividend • Dec 22Inaugural dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 1.4%.Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩117 (vs ₩121 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩6.91b (up 25% from 3Q 2020). Net income: ₩954.3m (down 2.2% from 3Q 2020). Profit margin: 14% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,600, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 34% over the past year.공시 • May 13Korea Bio-Gen Co.,Ltd announced that it has received KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorOn May 12, 2021, Korea Bio-Gen Co.,Ltd (KOSDAQ:A318000) closed the transaction.공시 • May 11Korea Bio-Gen Co.,Ltd announced that it expects to receive KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorKorea Bio-Gen Co., Ltd. (KOSDAQ:A318000) announced that it will issue series 3 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on May 10, 2021. The transaction will include participation from Core Mezzanine PJT Hedge Fund 2 for KRW 3,000,000,000 and existing investor Daegyeong Investment Co., Ltd. for KRW 2,000,000,000. The bonds does not bear any interest and matures on May 12, 2026. The bonds are convertible into 542,299 shares at a fixed conversion price of KRW 9,220 per share from May 12, 2022 to April 12, 2026. The expected subscription and payment date is May 12, 2021. The transaction is approved by the board of directors of the company.분석 기사 • Mar 02If You Had Bought Korea Bio-GenLtd (KOSDAQ:318000) Stock A Year Ago, You Could Pocket A 33% Gain TodayOn average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...공시 • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.분석 기사 • Feb 03The Trends At Korea Bio-GenLtd (KOSDAQ:318000) That You Should Know AboutWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩10,950, the stock is trading at a trailing P/E ratio of 30.4x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 63%.Is New 90 Day High Low • Jan 21New 90-day high: ₩10,950The company is up 48% from its price of ₩7,390 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period.Is New 90 Day High Low • Jan 04New 90-day high: ₩8,390The company is up 2.0% from its price of ₩8,260 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.분석 기사 • Dec 29Should You Be Impressed By Korea Bio-Gen Co.,Ltd's (KOSDAQ:318000) ROE?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Upcoming Dividend • Dec 22First Dividend Is ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 0.9%.분석 기사 • Dec 02Calculating The Intrinsic Value Of Korea Bio-Gen Co.,Ltd (KOSDAQ:318000)How far off is Korea Bio-Gen Co.,Ltd ( KOSDAQ:318000 ) from its intrinsic value? Using the most recent financial data...Is New 90 Day High Low • Oct 26New 90-day low: ₩6,880The company is down 4.0% from its price of ₩7,160 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.CEOSamuel Boo (39 yo)3.2yrs재임 기간Samuel Boo is Director of KBG Corp. and is its CEO since March 23, 2023.View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 15:28종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KBG Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea
공시 • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea
공시 • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.
공시 • Mar 13KBG Corp., Annual General Meeting, Mar 30, 2026KBG Corp., Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, goesan-gun, chungcheongbuk-do, South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 10 April 2026. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.3%).
분석 기사 • Nov 20KBG's (KOSDAQ:318000) Soft Earnings Don't Show The Whole PictureInvestors were disappointed with the weak earnings posted by KBG Corp. ( KOSDAQ:318000 ). However, our analysis...
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: ₩45.00 (vs ₩60.00 in 3Q 2024)Third quarter 2025 results: EPS: ₩45.00 (down from ₩60.00 in 3Q 2024). Revenue: ₩4.71b (down 24% from 3Q 2024). Net income: ₩391.8m (down 25% from 3Q 2024). Profit margin: 8.3% (down from 8.4% in 3Q 2024). The decrease in margin was driven by lower revenue.
공시 • Nov 07KBG Corp. announces Annual dividend, payable on April 10, 2026KBG Corp. announced Annual dividend of KRW 75.0000 per share payable on April 10, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Reported Earnings • May 18First quarter 2025 earnings released: EPS: ₩57.00 (vs ₩95.49 in 1Q 2024)First quarter 2025 results: EPS: ₩57.00 (down from ₩95.49 in 1Q 2024). Revenue: ₩6.09b (up 27% from 1Q 2024). Net income: ₩493.4m (down 41% from 1Q 2024). Profit margin: 8.1% (down from 17% in 1Q 2024). The decrease in margin was driven by higher expenses.
공시 • Feb 22KBG Corp., Annual General Meeting, Mar 24, 2025KBG Corp., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 44-86, sari-ro bangchukgol-gil, sari-myeon, goesan-gun, chungcheongbuk-do, South Korea
New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (₩42.0b market cap, or US$29.2m).
Buy Or Sell Opportunity • Jan 06Now 20% overvaluedOver the last 90 days, the stock has fallen 23% to ₩4,835. The fair value is estimated to be ₩4,029, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (2.2%).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩41.5b market cap, or US$28.9m).
Valuation Update With 7 Day Price Move • Dec 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩3,890, the stock trades at a trailing P/E ratio of 7.2x. Average trailing P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 52% over the past three years.
분석 기사 • Dec 06Earnings Working Against KBG Corp.'s (KOSDAQ:318000) Share Price Following 26% DiveTo the annoyance of some shareholders, KBG Corp. ( KOSDAQ:318000 ) shares are down a considerable 26% in the last...
Buy Or Sell Opportunity • Nov 18Now 23% overvaluedOver the last 90 days, the stock has fallen 25% to ₩4,930. The fair value is estimated to be ₩4,000, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.5% over the last 3 years, while earnings per share has been flat.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩6,040, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total loss to shareholders of 30% over the past three years.
New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩67.7b market cap, or US$50.7m).
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩7,750, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 4.7% over the past three years.
분석 기사 • Aug 06The Market Doesn't Like What It Sees From KBG Corp.'s (KOSDAQ:318000) Earnings Yet As Shares Tumble 29%KBG Corp. ( KOSDAQ:318000 ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩4,900, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total loss to shareholders of 44% over the past three years.
분석 기사 • May 21We Think That There Are Some Issues For KBG (KOSDAQ:318000) Beyond Its Promising EarningsKBG Corp.'s ( KOSDAQ:318000 ) healthy profit numbers didn't contain any surprises for investors. However the statutory...
Upcoming Dividend • Dec 20Inaugural dividend of ₩99.50 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 1.8%.
New Risk • Oct 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩83.9b market cap, or US$62.0m).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,600, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 46% over the past three years.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₩11,370, the stock trades at a trailing P/E ratio of 33.4x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 38% over the past three years.
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩8,900, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years.
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Shareholders have been diluted in the past year (5.7% increase in shares outstanding). Market cap is less than US$100m (₩115.7b market cap, or US$89.6m).
Valuation Update With 7 Day Price Move • May 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩14,340, the stock trades at a trailing P/E ratio of 39.9x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩16,260, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 213% over the past three years.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 57%After last week's 57% share price gain to ₩16,830, the stock trades at a trailing P/E ratio of 42.8x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 220% over the past three years.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩11,700, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 137% over the past three years.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩9,650, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 76% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. This is the first dividend for KBG since going public. The average dividend yield among industry peers is 2.4%.
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: ₩169 (vs ₩117 in 3Q 2021)Third quarter 2022 results: EPS: ₩169 (up from ₩117 in 3Q 2021). Revenue: ₩6.29b (down 9.1% from 3Q 2021). Net income: ₩1.39b (up 45% from 3Q 2021). Profit margin: 22% (up from 14% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩6,130, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩4,855, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩6,280, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total loss to shareholders of 27% over the past year.
Upcoming Dividend • Dec 22Inaugural dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 1.4%.
Reported Earnings • Nov 16Third quarter 2021 earnings released: EPS ₩117 (vs ₩121 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩6.91b (up 25% from 3Q 2020). Net income: ₩954.3m (down 2.2% from 3Q 2020). Profit margin: 14% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩10,600, the stock trades at a trailing P/E ratio of 21.4x. Average trailing P/E is 19x in the Chemicals industry in South Korea. Total returns to shareholders of 34% over the past year.
공시 • May 13Korea Bio-Gen Co.,Ltd announced that it has received KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorOn May 12, 2021, Korea Bio-Gen Co.,Ltd (KOSDAQ:A318000) closed the transaction.
공시 • May 11Korea Bio-Gen Co.,Ltd announced that it expects to receive KRW 5 billion in funding from Daegyeong Investment Co., Ltd. and another investorKorea Bio-Gen Co., Ltd. (KOSDAQ:A318000) announced that it will issue series 3 unregistered coupon nonguaranteed private convertible bond for gross proceeds of KRW 5,000,000,000 on May 10, 2021. The transaction will include participation from Core Mezzanine PJT Hedge Fund 2 for KRW 3,000,000,000 and existing investor Daegyeong Investment Co., Ltd. for KRW 2,000,000,000. The bonds does not bear any interest and matures on May 12, 2026. The bonds are convertible into 542,299 shares at a fixed conversion price of KRW 9,220 per share from May 12, 2022 to April 12, 2026. The expected subscription and payment date is May 12, 2021. The transaction is approved by the board of directors of the company.
분석 기사 • Mar 02If You Had Bought Korea Bio-GenLtd (KOSDAQ:318000) Stock A Year Ago, You Could Pocket A 33% Gain TodayOn average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
공시 • Feb 25Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021Korea Bio-Gen Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.
분석 기사 • Feb 03The Trends At Korea Bio-GenLtd (KOSDAQ:318000) That You Should Know AboutWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩10,950, the stock is trading at a trailing P/E ratio of 30.4x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 18x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 63%.
Is New 90 Day High Low • Jan 21New 90-day high: ₩10,950The company is up 48% from its price of ₩7,390 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period.
Is New 90 Day High Low • Jan 04New 90-day high: ₩8,390The company is up 2.0% from its price of ₩8,260 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.
분석 기사 • Dec 29Should You Be Impressed By Korea Bio-Gen Co.,Ltd's (KOSDAQ:318000) ROE?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Upcoming Dividend • Dec 22First Dividend Is ₩50.00 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. This is the first dividend for Korea Bio-GenLtd since going public. The average dividend yield among industry peers is 0.9%.
분석 기사 • Dec 02Calculating The Intrinsic Value Of Korea Bio-Gen Co.,Ltd (KOSDAQ:318000)How far off is Korea Bio-Gen Co.,Ltd ( KOSDAQ:318000 ) from its intrinsic value? Using the most recent financial data...
Is New 90 Day High Low • Oct 26New 90-day low: ₩6,880The company is down 4.0% from its price of ₩7,160 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period.